# Study to Evaluate the Effects of Two Doses of Seladelpar (MBX-8025) in Subjects With Primary Biliary Cirrhosis (PBC)

> **NCT02609048** · PHASE2 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 41 (actual)

## Conditions studied

- Primary Biliary Cirrhosis (PBC)

## Interventions

- **DRUG:** Placebo Comparator
- **DRUG:** Experimental: Seladelpar 50 mg
- **DRUG:** Experimental: Seladelpar / MBX-8025 200 mg

## Key facts

- **NCT ID:** NCT02609048
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-11-04
- **Primary completion:** 2016-07-01
- **Final completion:** 2016-07-01
- **Target enrollment:** 41 (ACTUAL)
- **Why stopped:** Study stopped early after review of safety and efficacy demonstrated efficacy proof-of-concept and need for dose reduction.
- **Last updated:** 2025-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02609048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02609048, "Study to Evaluate the Effects of Two Doses of Seladelpar (MBX-8025) in Subjects With Primary Biliary Cirrhosis (PBC)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02609048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*